 Zimmer Biomet has greatly underperformed the SP 500 as well as the iShares IHI, been stagnant over the past 5 years. The street consensus gives some hope for the projected growth with an estimated 28.67 FCF and 7.19 EBIT CAGR over the next 5 years. 